Live Analyst Rating Changes 54325 upgrades, downgrades & price-target moves · freshest Wall Street data, updated daily View live feed →
Analyst Tracker/Patrick B Donnelly
Citi

Patrick B Donnelly

Citi
Wall Street Analyst
★★★★★
#39
on 13Foresight · ranked by our own returns
72%
Success Rate
+18.5%
Average Return
47 of 65 calls profitable · +12.4% vs benchmark
S&P 500 (SPY)
📈 Across the calls we could measure, roughly 72% of Patrick B Donnelly's ratings turned a profit when each position was held for 1 year — averaging +18.5% per rating. These figures are computed by 13Foresight from historical prices, not supplied by the analyst.

Rating Distribution

63 Buy 41 Hold 3 Sell
Patrick's Stock Coverage 34 ratings · 2026-11-11
Company Date Position Consensus ⓘ Price Target ⓘ 1-Yr Return vs S&P 500 ⓘ
FTRE
Fortrea Holdings Inc.
 Oct 30, 2026 BUY Buy
+8.3% avg upside
13 analysts
$27.00
26.91% Upside
 -2.2% ·
ICLR
Icon
 Oct 29, 2026 HOLD Strong Buy
-1.8% avg upside
28 analysts
$215.00
1.66% Upside
 -5.0% ·
QGEN
Qiagen
 Oct 26, 2026 HOLD Buy
-10.5% avg upside
25 analysts
$52.00
3.62% Upside
 +0.4% ·
TMO
Thermo Fisher
 Oct 23, 2026 BUY Strong Buy
-5.1% avg upside
40 analysts
$800.00
14.84% Upside
 +6.6% ·
DHR
Danaher
 Oct 22, 2026 BUY Strong Buy
-4.4% avg upside
47 analysts
$270.00
16.28% Upside
 +2.8% ·
A
Agilent
 Aug 27, 2026 BUY Strong Buy
-8.0% avg upside
35 analysts
$190.00
8.69% Upside
 +13.2% ·
BRKR
Bruker
 Aug 05, 2026 HOLD Buy
+4.9% avg upside
22 analysts
$53.00
7.23% Downside
 +18.7% ·
ILMN
Illumina
 Aug 03, 2026 SELL Buy
-10.1% avg upside
32 analysts
$113.00
52.05% Downside
 -8.5% ·
MTD
Mettler-Toledo
 Jul 08, 2026 BUY Buy
-26.0% avg upside
19 analysts
$1550.00
7.44% Downside
 +39.1% ·
TXG
10x Genomics
 Jul 08, 2026 HOLD Buy
-7.5% avg upside
19 analysts
$45.00
35.90% Downside
 +38.9% ·
AVTR
Avantor
 Jul 08, 2026 HOLD Buy
+4.5% avg upside
27 analysts
$11.00
31.50% Downside
 +59.8% ·
GH
Guardant Health
 Jul 08, 2026 BUY Strong Buy
-3.1% avg upside
33 analysts
$215.00
20.26% Upside
 -0.5% ·
QDEL
QuidelOrtho
 Jul 08, 2026 HOLD Buy
+195.9% avg upside
13 analysts
$18.00
35.79% Upside
 -31.0% ·
CRL
Charles River Labs
 Jul 08, 2026 BUY Strong Buy
-28.5% avg upside
36 analysts
$265.00
26.23% Downside
 +55.0% ·
TECH
Bio-Techne
 Jun 29, 2026 HOLD Hold
+16.1% avg upside
21 analysts
$73.00
0.45% Upside
 +2.8% ·
SHC
Sotera Health
 May 28, 2026 BUY Buy
+20.0% avg upside
13 analysts
$23.00
26.79% Upside
 +19.8% ·
CAI
Caris Life Sciences, Inc.
 May 08, 2026 BUY Strong Buy
-9.5% avg upside
21 analysts
$28.00
18.40% Downside
 +51.3% ·
MDLN
Medline
 May 06, 2026 BUY Strong Buy
+43.4% avg upside
27 analysts
$55.00
71.31% Upside
 -2.6% ·
WST
West Pharmaceutical Services
 Apr 24, 2026 BUY Strong Buy
-6.0% avg upside
18 analysts
$400.00
2.97% Downside
 +35.1% ·
NTRA
Natera
 Apr 07, 2026 BUY Strong Buy
-13.3% avg upside
28 analysts
$300.00
27.64% Downside
 +2.2% ·
IQV
IQVIA Holdings
 Apr 07, 2026 HOLD Strong Buy
-2.5% avg upside
40 analysts
$200.00
25.22% Downside
 +61.3% ·
WAT
Waters
 Apr 07, 2026 BUY Strong Buy
-12.6% avg upside
31 analysts
$425.00
8.09% Downside
 +54.7% ·
STVN
Stevanato Group
 Apr 07, 2026 BUY Buy
+38.1% avg upside
14 analysts
$26.00
34.24% Upside
 +42.2% ·
BIO
Bio-Rad Laboratories
 Apr 07, 2026 HOLD Buy
-3.1% avg upside
9 analysts
$300.00
19.32% Downside
 +39.0% ·
DGX
Quest Diagnostics
 Feb 11, 2026 HOLD Buy
-26.4% avg upside
34 analysts
$215.00
14.53% Downside
 +25.0% ·
LH
Labcorp Holdings
 Jan 02, 2026 BUY Strong Buy
-21.6% avg upside
38 analysts
$325.00
10.00% Downside
 +46.7% ·
RVTY
Revvity
 May 22, 2025 BUY Buy
-19.9% avg upside
25 analysts
$135.00
13.94% Downside
 +7.5% ·
OSUR
Orasure Technologies
 Feb 26, 2025 BUY Buy
+111.5% avg upside
12 analysts
$6.00
52.30% Upside
 +0.7% ·
SERA
Sera Prognostics
 Mar 23, 2023 HOLD Strong Buy
+265.1% avg upside
8 analysts
$4.25
108.26% Upside
 +163.8% ·
BEAM
Beam Therapeutics
 Mar 01, 2023 BUY Strong Buy
+91.1% avg upside
25 analysts
$62.00
127.65% Upside
 +3.5% ·
PSNL
Personalis
 Feb 24, 2023 BUY Buy
-6.1% avg upside
11 analysts
$6.00
62.02% Downside
 -56.6% ·
ADPT
Adaptive Biotechnologies
 Aug 14, 2019 HOLD Strong Buy
+1.9% avg upside
17 analysts
$36.00
35.14% Upside
 -9.6% ·
TTOO
T2 Biosystems
 Nov 30, 2018 HOLD Buy
+1015078.6% avg upside
10 analysts
$4.50
642757.11% Upside
 · ·
MYGN
Myriad Genetics
 Nov 30, 2018 HOLD Sell
+159.8% avg upside
24 analysts
$32.00
403.99% Upside
 -20.2% ·
🔒 29 more ratings — with price targets, crowd consensus and our measured returns.
Sign in free to unlock See Pro plans
Free account unlocks every analyst's full coverage table.
Patrick B Donnelly — Frequently Asked Questions
How accurate are Patrick B Donnelly's stock ratings?
Based on the calls 13Foresight could measure, about 72% of Patrick's ratings were profitable over a one-year hold, with an average return of +18.3% per rating, or +12.2% versus the S&P 500. We score every analyst the same way, from historical prices. Each return is measured in the stock's own trading currency, so for non-US listings the S&P 500 comparison leaves out currency moves.
How is Patrick ranked on 13Foresight?
Patrick B Donnelly is currently ranked #39 with a 5-star rating. Our rank blends hit rate, average return versus the market, and how many calls we have to judge — so a long, consistent record outweighs a few lucky picks. It is our own calculation, updated daily.
Which stocks does Patrick cover?
Patrick most recently has ratings on FTRE, ICLR, QGEN, TMO, DHR, A, BRKR, ILMN, MTD, TXG, AVTR, GH and 22 more. See the full coverage table above for positions, price targets and our measured returns.
Where can I see other analyst ratings?
Browse the full analyst leaderboard to compare Wall Street analysts ranked by their measured performance, success rate and average return.

Disclaimer: 13Foresight compiles analyst ratings and price targets from publicly available sources. Performance metrics, rankings and star ratings shown here are calculated independently by 13Foresight from historical market prices and may differ from figures published elsewhere. This information may be incomplete, delayed or inaccurate, is provided for research and informational purposes only, and is not investment advice. The underlying ratings and opinions are those of the respective analysts and their firms; 13Foresight accepts no liability for any decisions made based on this data.